NCT00986232已完成2 期
A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,551
- 主要终点
- Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units
研究概览
简要总结
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Months 至 23 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In good health
- •Negative clinical history of measles, mumps, rubella, varicella, and zoster
排除标准
- •Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination
- •Any immune impairment or deficiency
- •Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination
- •Vaccination with an inactive vaccine with in the past 14 days
- •Vaccination with a live vaccine within the past 30 days
- •Immune globulin or any blood product administered in the past 3 months
结局指标
主要结局
Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units
时间窗: 6 weeks postvaccination
Antibody response to Varicella at 6 weeks postvaccination in participants with baseline titer \<1.25 gpELISA units
次要结局
- Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 207.5 mIU/mL(6 weeks postvaccination)
- Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 2.0 Ab Units/mL(6 weeks Postvaccination)
- Antibody Response to Measles at 6 Weeks Postvaccination in Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)(6 weeks Postvaccination)
- Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL(6 weeks Postvaccination)
- Antibody Response to Rubella at 6 Weeks Postvaccination in Participants Initially Seronegative to Rubella at Baseline - Geometric Mean Titer (GMT)(6 weeks postvaccination)
- Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences (CAEs)(6 weeks Postvaccination Visit 1 or Visit 2)
- Antibody Response to Varicella at 6 Weeks Postvaccination in Participants With Baseline Titer < 1.25 gpELISA Units - Geometric Mean Titer (GMT)(6 weeks Postvaccination)
- Antibody Response to Mumps at 6 Weeks Postvaccination in Participants Initially Seronegative to Mumps at Baseline - Geometric Mean Titer (GMT)(6 weeks Postvaccination)
研究者
相似试验
终止
3 期
A Study of ProQuad™ in Healthy Children in Korea (V221-023)MeaslesVaricellaRubellaMumpsNCT00839917Merck Sharp & Dohme LLC30
已完成
3 期
Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesMeaslesMumpsRubellaVaricellaNCT00984295Merck Sharp & Dohme LLC1,913
已完成
3 期
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)MeaslesVaricellaPoliomyelitisHaemophilus InfectionsRubellaHepatitis BMumpsDiphtheriaPertussisTetanusNCT00432042Merck Sharp & Dohme LLC955
已完成
4 期
Intranasal Dexmedetomidine Versus Intranasal Midazolam for Emergence Delirium PreventionEmergence DeliriumNCT04263844Indonesia University66
已完成
2 期
Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure InfectionSkin InfectionsNCT00671580Protez Pharmaceuticals, Inc.99